Medical network on August 17 - cardiovascular disease (CVD) is a kind of disease, serious harm human health in recent years, whether in international or domestic, morbidity and mortality of this disease is obvious rise, seriously affecting people's life and health security. Since the late 1980s, with the introduction of a large number of cholesterol-lowering drugs, statins have become increasingly popular, and lipotherapy has become a major preventive measure for cardiovascular disease.
, according to data from the global blockbuster drugs statins in 2016, global sales of over $3 billion in a comfortable cut statin, close to $2 billion with atorvastatin, more than $1 billion in a compound simvastatin/in accordance with the folding mab. Statin sample hospitals, according to data in the sample hospitals sales of more than 1 billion yuan of atorvastatin, 500 million ~ 1 billion yuan rui shu laval statin, 100 million ~ 500 million yuan of a horse in statin, simvastatin, pravastatin. The statins market has long been a big hit.
In terms of the current clinically common fat-regulating drugs, statins are still strong, leading the market for lipid lowering, which is the preferred drug for lowering LDL cholesterol (ldl-c). However, there are still a large number of patients who can't take statins and other available therapies. In order to solve the clinical needs, the new type fat-regulating PCSK9 inhibitor has become a new target for drug companies.
The PCSK9 inhibitor is a class of single anti-drug, which can significantly reduce the ldl-c and its effectiveness is stronger than the current high dose of statin. The two listed products are the anjin (Repatha) (Repatha), the sanofi/recycled yuan (Praluent). From the point of PCSK9 inhibitors of market performance in 2016, due to the expensive, listed in the early did not start, so in the short term PCSK9 inhibitors are difficult to dominate, cholesterol-lowering drugs market is still a world of statins.
International market slowdown
At present, the statins in the lipid market are: rishuvastatin, atorvastatin, simvastatin, prevastatin, fluorostatin, lovastatin, pivastatin; The compound preparations include simvastatin/ezebutamine, arvastatin/amlodipine, lovastatin/nicotinic acid and more than 10 varieties. In 2016, the more outstanding products in the global market were atorvastatin, rishuvastatin and compound simvastatin/ezebutamine products.
According to the world's best-selling drug data statistics, the total market value of the five main products of statins in 2005 and 2011 remained above $20 billion. In 2012-2015, the total market of five major products of statins remained at about $10 billion. In 2016, the total market value of the five main products of statins was only us $6.58 billion. The global statins market continues to decline rapidly, mainly due to the patent expiration of blockbuster products and the result of a patent cliff.
In 2016, the world's bestselling first five big statins are: rui shu laval statin, atorvastatin, compound simvastatin in accordance with the folding mab, simvastatin and pravastatin, sales of $3.4 billion and $1.76 billion respectively, $1.14 billion, $178 million and $093 million.
Figure 1. Sales trend of the major products of statin drugs in the world from 2005 to 2016 (unit: million usd)
In 2016, the global statins sales in the top five companies are respectively: astrazeneca (Crestor, Crestor), Pfizer Lipitor, Lipitor, MSD (remains to can, Vytorin), Merck's off (concerned), daiichi sankyo hundred merlot town (Pravachol). Lipitor, a brand of astrazeneca, continues to lead the statins market.
Atorvastatin as the world's top lipid drug, since listing has achieved outstanding results, eight years in a row in 2004-2004 sales of more than $10 billion, 2006 sales peaked at $13.7 billion. The patent expires in 2011, and with the expiry of the us patent and the increasingly competitive market for statins, atorvastatin has been on a rapid downward trend since 2011.
Domestic market is strong
Compared with the rapid decline in the international market of statins, the domestic market has increased rapidly. Since 2006, atorvastatin has been at the top of the market in the domestic sample hospital market, which has been the leading market in the market for blood lipids. Another outstanding product r comfortable cut statin went public in 2007, 2012, beyond simvastatin, successful superior domestic statin second flagship product, keep up to now, and as with atorvastatin in the positive direction.
Samples of domestic hospitals, according to data from 2005 to 2016, statins sales, sales of 240 million yuan in 2005, 2016 annual sales of 2016 yuan, 11 years to 12 times more than the overall market growth, and has a tendency to increase year by year. The compound growth rate of drug purchase in 2005-2016 was 25.7%, which was well above the drug industry average. In addition, the proportion of the total amount of drugs sold by statins has increased year by year.
In 2016, involving cholesterol-lowering drugs of domestic product has 30, from the point of sales, the top 10 products, statins products have seven, atorvastatin, rui shu laval statin, horse statin, simvastatin, pravastatin, fluorine cut statin, compound atorvastatin amlodipine, 90.5% of cholesterol-lowering drugs market share, shows a high concentration. Of these, atorvastatin accounted for 48.9%, rishu vastatin was 23.4% and the other five products accounted for 18.2%. Atorvastatin, which has nearly half the market share of blood lipids, has led the way, with rishuvastatin not trailing behind.
Figure 2 sales trend of the main products of statin drugs in China from 2005 to 2016 (unit: ten thousand yuan)
Involving statin drugs to the current domestic enterprise nearly 50, from the point of sales in 2016, performance outstanding enterprise's top five products are: dalian Pfizer's atorvastatin (lipitor, sales of 1.21 billion yuan), jiangsu rui shu of astrazeneca pharmaceutical statin (crestor, sales of 550 million yuan), Beijing jia Lin pharmaceutical atorvastatin (ALe, sales of 250 million yuan), CRC piece cut statin double crane pharmaceutical sales (120 million yuan), Shanghai three pharmaceutical pravastatin sales ($104 million), market share of 41.3%, 18.8%, 8.4%, 4.2% and 3.5%, other enterprises accounted for 23.7%.
Figure 3 market pattern of statins in China in 2016 (unit: %)
In statin top five products, foreign enterprise dalian Pfizer and astrazeneca statin products in jiangsu has maintained high growth and rising trend, the domestic enterprise Beijing jia Lin pharmaceutical with atorvastatin (ALe) in statin gain a foothold in the market.
Although the patent expires, domestic products have not been able to break the monopoly pattern due to the long-term occupation of the market of lipid-lowering drugs. |
